CT Radiomics Predicts PFS from CDK4/6 Inhibitor Plus Endocrine Therapy in Advanced Breast Cancer

Combined radiomics-clinical model from baseline CT predicted PFS in HR+/HER2- advanced breast cancer on CDK4/6 inhibitor + endocrine therapy (C-index 0.85 training, 0.76 testing) but requires external validation.

• Time-dependent AUCs for PFS at 6, 12, and 18 months were 0.938, 0.785, and 0.836 in the test set.
• For treatment response, the best overall response model achieved an AUC of 0.80 and the early response model an AUC of 0.70.
• Findings are exploratory from a small retrospective cohort (n=102) with a test set of only 20 patients; validation in larger multicenter cohorts is needed.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.